Literature DB >> 9620119

Elevated pancreatic enzymes after extended propofol therapy.

C J Possidente1, F B Rogers, T M Osler, T A Smith.   

Abstract

Propofol is a sedative hypnotic agent often administered for intensive care sedation. A 28-year-old man who suffered a severe head injury developed elevated pancreatic enzymes after receiving extended high-dosage propofol therapy. Amylase and lipase values gradually reduced toward normal after the drug was discontinued. Possible propofol-induced pancreatitis was reported with short-term but not with prolonged therapy. A definitive cause-and-effect relationship is unclear since head trauma also was reported to cause elevated pancreatic enzymes. Intensive care practitioners should be aware of this potential reaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620119

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

Review 1.  Acute pancreatitis after single-dose exposure to propofol: a case report and review of literature.

Authors:  Qaiser Jawaid; Michael E Presti; Brent A Neuschwander-Tetri; Frank R Burton
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 2.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Pancreotoxicity of Propofol Sedation during Purulent Meningitis : What is the Role for Octreotide?

Authors:  Roberto Manfredi; Nicola Dentale; Lorenza Fortunato; Michele Pavoni; Leonardo Calza; Francesco Chiodo
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 4.  Propofol: a review of its use in intensive care sedation of adults.

Authors:  Kate McKeage; Caroline M Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.